Evelyne Nguyen
Directeur Financier/CFO chez BIOM'UP
Profil
Evelyne Nguyen is currently the Director-Administrative & Financial at Biom'Up SA and the Chief Financial Officer at EUROAPI SA. Previously, she held positions as Director at LFB Biotechnologies SASU and rEVO Biologics, Inc., Chief Financial Officer at Nicox SA, Chief Financial & Strategy Officer at Laboratoire Français du Fractionnement et des Biotechnologies, and President at MAbgène SA. She also served as the Chief Financial Officer at Biophytis SA from 2020 to 2022.
Ms. Nguyen obtained her undergraduate degrees from Stanford University and Institut Supérieur de Gestion.
Postes actifs de Evelyne Nguyen
| Sociétés | Poste | Début |
|---|---|---|
| BIOM'UP | Directeur Financier/CFO | - |
| EUROAPI | Directeur Financier/CFO | 14/05/2024 |
Anciens postes connus de Evelyne Nguyen
| Sociétés | Poste | Fin |
|---|---|---|
| BIOPHYTIS S.A. | Directeur Financier/CFO | 05/04/2022 |
| NICOX SA | Directeur Financier/CFO | - |
LFB Biotechnologies SASU
 LFB Biotechnologies SASU BiotechnologyHealth Technology LFB Biotechnologies SASU provides plasma-derived medicinal products. The firm undertakes research and development programs in plasma fractions and biotechnologies in the areas of autoimmune diseases and hemostasis disorders. The company was founded on September 21, 2006 and is headquartered in Courtaboeuf, France. | Directeur/Membre du Conseil | - |
MAbgène SA
 MAbgène SA BiotechnologyHealth Technology MAbgène SA is a French company that produces monoclonal antibodies and recombinant proteins through cell culture. The company is based in Alès, France. The company has two CLD platforms available, including a CHO-S platform and their proprietary EMABling® platform. LFB Biotechnologies SASU is a subsidiary of LFB BIOMANUFACTURING, which is ultimately controlled by the Government of France. MAbgène was acquired by LFB Biotechnologies SASU on November 30, 2007 for $4.09 million. | President | - |
| REVO BIOLOGICS INC | Directeur/Membre du Conseil | - |
Formation de Evelyne Nguyen
| Stanford University | Undergraduate Degree |
| Institut Supérieur de Gestion | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| NICOX SA | Health Technology |
| BIOPHYTIS S.A. | Health Technology |
| EUROAPI | Health Technology |
| Entreprise privées | 5 |
|---|---|
LFB Biotechnologies SASU
LFB Biotechnologies SASU BiotechnologyHealth Technology LFB Biotechnologies SASU provides plasma-derived medicinal products. The firm undertakes research and development programs in plasma fractions and biotechnologies in the areas of autoimmune diseases and hemostasis disorders. The company was founded on September 21, 2006 and is headquartered in Courtaboeuf, France. | Health Technology |
Laboratoire Français du Fractionnement et des Biotechnologies
 Laboratoire Français du Fractionnement et des Biotechnologies BiotechnologyHealth Technology Laboratoire Francais du Fractionnement et des Biotechnologies SA provides plasma-derived medicinal products. It undertakes research and development programs in plasma fractions and biotechnologies in the areas of autoimmune diseases and hemostasis disorders. The firm's products include albumin and immunoglobulin. It also offers products for rare pathologies. The company was founded in 1994 and is headquartered in Les Ulis, France. | Health Technology |
MAbgène SA
MAbgène SA BiotechnologyHealth Technology MAbgène SA is a French company that produces monoclonal antibodies and recombinant proteins through cell culture. The company is based in Alès, France. The company has two CLD platforms available, including a CHO-S platform and their proprietary EMABling® platform. LFB Biotechnologies SASU is a subsidiary of LFB BIOMANUFACTURING, which is ultimately controlled by the Government of France. MAbgène was acquired by LFB Biotechnologies SASU on November 30, 2007 for $4.09 million. | Health Technology |
Biom'Up SA
 Biom'Up SA Medical SpecialtiesHealth Technology Biom'Up SA engages in the development of hemostatic product composed of patent-protected biopolymers. Its products include Hemoblast Bellows and Hemosnow. The company was founded by Patricia Forest, Sylvain Picot and Christian Gagnieu on February 21, 2005 and is headquartered in Lyon, France. | Health Technology |
rEVO Biologics, Inc.
 rEVO Biologics, Inc. BiotechnologyHealth Technology rEVO Biologics, Inc. engages in the development and commercialization of specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions. Its products include ATryn, which prevents blood clots during and after surgery and childbirth for patients with hereditary antithrombin deficiency. The company was founded in February 1993 and is headquartered in Framingham, MA. | Health Technology |
